Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TENOFOVIR | 300MG | TABLET | Resolved | 2020-09-30 | 2020-11-16 | 125338 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2017-09-27 | 2017-10-24 | 23655 |
| APO-TERAZOSIN | 10MG | TABLET | Resolved | 2018-10-02 | 2018-12-27 | 62871 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2018-02-01 | 2018-08-20 | 37986 |
| APO-TERAZOSIN | 10MG | TABLET | Resolved | 2023-06-16 | 2024-05-10 | 195259 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2018-01-17 | 2018-07-31 | 36353 |
| APO-TERAZOSIN | 10MG | TABLET | Resolved | 2018-01-17 | 2018-07-31 | 36350 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2018-10-19 | 2018-12-27 | 65008 |
| APO-TERAZOSIN | 1MG | TABLET | Resolved | 2018-01-31 | 2018-07-31 | 37743 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2024-04-26 | 2024-05-10 | 226330 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2024-04-12 | 2024-05-10 | 224999 |
| APO-TERAZOSIN | 1MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195250 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195256 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195253 |
| APO-TERAZOSIN | 1MG | TABLET | Resolved | 2017-06-28 | 2017-10-17 | 14250 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-01-31 | 2018-09-21 | 37746 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-07-22 | 2022-09-01 | 165335 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2017-08-08 | 2017-09-22 | 18567 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2024-05-03 | 2024-07-26 | 227065 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-07 | 2023-12-22 | 203843 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 9MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110977 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |